AstraZeneca’s Mene Pangalos awarded knighthood in the New Year 2020 Honours List

Mene Pangalos, Executive Vice President of BioPharmaceuticals Research and Development, has been awarded a knighthood by Her Majesty The Queen in the New Year 2020 Honours List in recognition of his services to UK science.


Based in Cambridge, Mene has overall responsibility for AstraZeneca’s research and development (R&D) activities in BioPharmaceuticals. Since joining in 2010, he has pioneered programmes to promote novel Open Innovation partnerships with non-governmental and peer organisations, and more than 200 academic institutions to help drive the UK’s position as a world leader in life sciences R&D.

Mene has also been the driving force behind an almost five-fold improvement in R&D productivity at AstraZeneca, measured by the number of pipeline molecules advancing from preclinical investigation to completion of Phase III clinical trials.

CEO Pascal Soriot interviews Sir Mene Pangalos:

Mene Pangalos said: “I am truly humbled and immensely honoured to receive this award and feel incredibly fortunate to have worked alongside so many talented colleagues and collaborators through my career. The UK is one of the best places in the world to do applied research, and life sciences clusters such as the one in Cambridge drive the convergence of scientific innovation and talent, enabling us to better turn science into life-changing medicines.”

Pascal Soriot, Chief Executive Officer at AstraZeneca, said: “Mene’s knighthood is fitting recognition of his outstanding talent and commitment to UK science and drug discovery which is helping bring innovative new medicines to patients around the world. He has driven the transformation of research and development at AstraZeneca, with a remarkable improvement in productivity in recent years, and he is now accelerating efforts in the digital transformation of R&D.”

Professor Dame Nancy Rothwell, President and Vice-Chancellor of the University of Manchester, UK, said “Mene has long been a champion of promoting and strengthening UK science through uniquely open ways of working between industry, academic, non-governmental and peer organisations. I am immensely proud to have worked alongside Mene across a number of collaborations to advance our understanding of complex disease and translate this into human benefit. Congratulations Sir Mene!”

Mene has made outstanding contributions throughout his career to UK science. He is a Fellow of the Academy of Medical Sciences, the Royal Society of Biology and Clare Hall, University of Cambridge. He sits on the Medical Research Council, co-chairs the Life Sciences Council Expert Group on Innovation, Clinical Research and Data, and is a member of the UK Life Sciences Industrial Strategy Implementation Board. He sits on the boards of The Francis Crick Institute, Cambridge University’s Judge Business School and Dizal Pharma, and is a member of the Royal Society's Science, Industry and Translation Committee.

Mene has held Visiting Professorships at King’s College London and the University of Pennsylvania and is the holder of honorary degrees from Glasgow University and Imperial College London. In 2019, Mene received the Greek Prix Galien Scientific Researcher Award.

About AstraZeneca

AstraZeneca (LSE/STO/NYSE: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas - Oncology, Cardiovascular, Renal and Metabolism, and Respiratory. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. Please visit and follow the Company on Twitter @AstraZeneca.



Media Relations



Gonzalo Viña


+44 203 749 5916

Rob Skelding


+44 203 749 5821

Rebecca Einhorn


+1 301 518 4122

Matt Kent


+44 203 749 5906

Jennifer Hursit


+44 203 749 5762

Christina Malmberg Hägerstrand


+46 8 552 53 106

Michele Meixell


+1 302 885 2677


Investor Relations



Thomas Kudsk Larsen


+44 203 749 5712

Henry Wheeler


+44 203 749 5797

Christer Gruvris

BioPharmaceuticals (Cardiovascular, Metabolism)

+44 203 749 5711

Nick Stone

BioPharmaceuticals (Renal) Environmental, Social and Governance

+44 203 749 5716

Josie Afolabi

BioPharmaceuticals (Respiratory)

Other medicines

+44 203 749 5631

Craig Marks


Fixed income

+44 7881 615 764

Jennifer Kretzmann

Corporate access

Retail investors

+44 203 749 5824

US toll-free


+1 866 381 72 77



  • Corporate and financial